CAR-T therapy for gastrointestinal cancers: current status, challenges, and future directions

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is effective against blood cancers.
• Its use in solid tumors, especially gastrointestinal (GI) cancers, is limited by antigen selection, tumor microenvironment complexity, and toxicity.
• GI cancers include esophageal, gastric, colorectal, pancreatic, and liver cancers.

Purpose of the Study:

• To review the current status of CAR-T therapy in GI cancers.
• To discuss the challenges and limitations of applying CAR-T therapy to solid tumors.
• To highlight innovative strategies for advancing CAR-T therapy in GI cancers.

Main Methods:

• Literature review of current CAR-T therapy research in GI cancers.
• Analysis of challenges including target antigen identification and tumor microenvironment.
• Exploration of novel CAR-T strategies such as multispecific and armored CAR-T cells.

Main Results:

• CAR-T therapy has shown potential but faces significant obstacles in GI cancers.
• Key challenges include identifying suitable tumor antigens and overcoming the immunosuppressive tumor microenvironment.
• New approaches like multispecific CAR-T cells and armored CAR-T cells are emerging.

Conclusions:

• Advancements in CAR-T therapy for GI cancers require addressing current limitations.
• Innovative strategies are crucial for improving efficacy and safety in solid tumors.
• Further research is needed to fully realize the potential of CAR-T therapy in treating GI malignancies.